Amarantus Bioscience Holdings, Inc announced that it has entered into a definitive agreement of 300 12% series I convertible preferred stock at a price of $5,000 for gross proceeds of up to 1,500,000 on February 26, 2018. The transaction will include participation from an institutional investor. The transaction will take place in up to five tranches of $300,000 each. Each share of preferred stock is convertible into common stock at a fixed price of $0.07 per share.